Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Weide, Benjamin; Martens, Alexander; C. Hassel, Jessica; Berking, Carola; A. Postow, Michael; Bisschop, Kees; Simeone, Ester; Mangana, Johanna; Schilling, Bastian; Maria Di Giacomo, Anna; Brenner, Nicole; C. Kähler, Katharina; Heinzerling, Lucie; Gutzmer, Ralf; Bender, Armin; Gebhardt, Christoffer; Romano, Emanuela; Meier, Friedegund; Martus, Peter; Maio, Michele; U. Blank, Christian; Schadendorf, Dirk; Dummer, Reinhard; A. Ascierto, Paolo; A.P. Hospers, Geke; Garbe, Claus; D. Wolchok, Jedd

doi:10.1158/1078-0432.ccr-16-0127

Public

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Published in Clinical Cancer Research • May 16, 2016

Authors:

Benjamin Weide

Alexander Martens

Jessica C. Hassel

Abstract

PURPOSE: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) after pembrolizumab treatment in melanoma patients. EXPERIMENTAL DESIGN:...

Subject

Pembrolizumab

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!